ARDC Research Link Australia Research Link Australia   BETA Research
Link
Australia
  • ARDC Newsletter Subscribe
  • Contact Us
  • Home
  • About
  • Feedback
  • Explore Collaborations
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation
  • Researcher
  • Funded Activity
  • Organisation

Need help searching? View our Search Guide.

Advanced Search

Current Selection
Australian State/Territory : VIC
Research Topic : CLINICAL TRIAL
Field of Research : Infectious Diseases
Clear All
Filter by Field of Research
Infectious Diseases (7)
Clinical Sciences (4)
Biochemistry And Cell Biology Not Elsewhere Classified (1)
Developmental Genetics (incl. Sex Determination) (1)
Dynamical Systems (1)
Humoral Immunology And Immunochemistry (1)
Infectious Agents (1)
Medical Parasitology (1)
Medical Virology (1)
Microbial Genetics (1)
Filter by Socio-Economic Objective
Infectious diseases (3)
Prevention—biologicals (e.g. vaccines) (2)
Child health (1)
Endocrine organs and diseases (incl. diabetes) (1)
Expanding Knowledge in the Medical and Health Sciences (1)
Other (1)
Treatments (e.g. chemicals, antibiotics) (1)
Filter by Funding Provider
Australian Research Council (4)
National Health and Medical Research Council (3)
Filter by Status
Closed (7)
Filter by Scheme
Discovery Projects (2)
NHMRC Project Grants (2)
ARC Future Fellowships (1)
Linkage Infrastructure, Equipment and Facilities (1)
Project Grants (1)
Filter by Country
Australia (7)
Filter by Australian State/Territory
VIC (7)
NSW (3)
ACT (1)
NT (1)
  • Researchers (8)
  • Funded Activities (7)
  • Organisations (16)
  • Funded Activity

    The Arthroplasty Surgical Antibiotic Prophylaxis (ASAP) Study

    Funder
    National Health and Medical Research Council
    Funding Amount
    $3,509,985.00
    Summary
    The demand for total joint replacement surgery will double over the next decade. Infection involving the surgical wound is a devastating complication of this surgery. Half of all infections are due to methicillin resistant Staphylococcus (such as MRSA) and Enterococcus. This multicentre randomised controlled trial aims to investigate whether the addition of vancomycin at the time of surgery reduces the incidence of surgical wound infections; is safe and is cost-effective.
    More information
    Funded Activity

    A Study To Investigate Alternative Regimens For Pneumococcal Vaccination Of Infants In A Developing Country

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,622,210.00
    Summary
    Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver thi .... Streptococcus pneumoniae (Pnc) is the leading vaccine preventable cause of serious infection in infants. The current Pnc conjugate vaccine is very expensive (approximately USD $200-infant) so it is unlikely to be affordable for most developing countries. Moreover, as health care access in developing countries may be episodic and unreliable, many children do not receive either complete or timely vaccine courses. Therefore, it is important to investigate affordable and flexible ways to deliver this vaccine, which are safe and effective. A recent WHO-GAVI meeting to address impediments to the introduction of these vaccines in developing countries recognized the need to evaluate other regimens of Pnc conjugate vaccine as an important research priority. This study has been deliberately formulated with that need in mind. The site for this research is Fiji. Although health services are good, Pnc disease, particularly pneumonia, remains the commonest cause of childhood morbidity and mortality. Fiji has good vaccine coverage and was the first Pacific country to introduce Hib vaccine. The arrival of the new, expensive Pnc conjugate vaccine presents a dilemma for Fiji and many similar countries. The expense of this vaccine would consume a large portion of the health budget. This study has two components: 1. A Phase 2 immunogenicity study (involving 750 infants) to evaluate regimens using reduced numbers of doses of Pnc conjugate vaccine, and using timing of dosing and combinations with the Pnc polysaccharide (PS) vaccine that may be more suited to the epidemiology of Pnc disease in developing countries. 2. An epidemiological study will measure the burden of invasive Pnc disease and pneumonia in Fiji. This will be part of a global effort to address these issues, and will be used to develop rapid assessment tools for these diseases in developing countries. We will seek cofounding for this component.
    Read more Read less
    More information
    Funded Activity

    The Clinical Value Of Serology And Molecular Tests For Diagnosing Invasive Aspergillosis In At-risk Hematology Patients

    Funder
    National Health and Medical Research Council
    Funding Amount
    $1,095,500.00
    Summary
    Aspergillus is a fungus found in soil, on farms and on construction sites. In those whose immune system is impaired it causes severe infection. The people who are particularly at high-risk of Aspergillus infection (called Invasive Aspergillosis) are those with acute leukaemia on chemotherapy or post bone marrow transplantation. Currently 15% of those at high-risk get Invasive Aspergillosis and 58-93% of those infected die. The main reason for this high death rate is that our current diagnostic t .... Aspergillus is a fungus found in soil, on farms and on construction sites. In those whose immune system is impaired it causes severe infection. The people who are particularly at high-risk of Aspergillus infection (called Invasive Aspergillosis) are those with acute leukaemia on chemotherapy or post bone marrow transplantation. Currently 15% of those at high-risk get Invasive Aspergillosis and 58-93% of those infected die. The main reason for this high death rate is that our current diagnostic tests are not good at detecting infection or often only detect the infection at advanced stages when treatment is ineffective. Because of the limitations of current diagnostic tests the current practice is to give empiric antifungal therapy (EAFT) early to treat Invasive Aspergillosis. However studies have demonstrated that this therapy has only resulted in a minor reduction in the mortality rates and it causes significant drug toxicity. It is a suboptimal treatment modality. New tests have been developed to diagnose Invasive Aspergillosis. These tests are for the detection of an Aspergillus protein in blood and for the detection of Aspergillus DNA in the blood. Available data suggests that these new tests are sensitive in the detection of Invasive Aspergillosis. Also other studies suggest that these new tests make an early diagnosis and seem to be able to monitor responses to treatment. However no study has been performed to date which demonstrates that the use of these tests can impact on important patient outcomes. This trial is designed to determine whether the use of the new tests to guide therapy will help improve treatment of Invasive Aspergillosis, reduce drug toxicity and reduce the death rate in the high-risk patients as compared with the current standard method of diagnosis and treatment with EAFT. If the trial is successful then this represents a significant advancement in the treatment and survival of leukaemic and bone marrow transplantation patients.
    Read more Read less
    More information
    Funded Activity

    Discovery Projects - Grant ID: DP0987339

    Funder
    Australian Research Council
    Funding Amount
    $510,000.00
    Summary
    The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in .... The dynamics of viral latency in chronic infection. Although many acute infections can now be controlled, we still suffer from a large number of chronic infections such as HIV or herpes that cannot be eradicated. Many of these infections persist because they can lie dormant in a 'latent' state. How this latent state is established, and how long it lasts are important to understand if we want to control these infections. We have assembled a team of mathematicians, immunologists and virologists in order to study latent infection at the cellular level, and within infected monkeys. This will provide the first insights into the dynamics of latency - how these cells are produced and die - and should lead to novel approaches to controlling chronic infection.
    Read more Read less
    More information
    Funded Activity

    ARC Future Fellowships - Grant ID: FT0992317

    Funder
    Australian Research Council
    Funding Amount
    $686,400.00
    Summary
    Identifying the major targets of protective antibodies against malaria. This project aims to understand how immunity to malaria develops and to use this knowledge to develop effective vaccines against malaria. The development of a malaria vaccine would be of great value in Australia's region where malaria is a leading cause of death and illness and impairs economic development. The project will advance our knowledge of how the immune system fights infections and will contribute to building Austr .... Identifying the major targets of protective antibodies against malaria. This project aims to understand how immunity to malaria develops and to use this knowledge to develop effective vaccines against malaria. The development of a malaria vaccine would be of great value in Australia's region where malaria is a leading cause of death and illness and impairs economic development. The project will advance our knowledge of how the immune system fights infections and will contribute to building Australia's strength in infectious diseases research and developing strategies to combat important infections. The project will help build and maintain expertise in developing vaccines in Australia and the approaches used and knowledge gained will be applicable to understanding and combating other important infections.
    Read more Read less
    More information
    Funded Activity

    Discovery Projects - Grant ID: DP160104980

    Funder
    Australian Research Council
    Funding Amount
    $486,700.00
    Summary
    Developmental genetics of malaria parasites. This project aims to improve our understanding of malarial genetics. The sexual cycle of malaria parasites occurs in mosquitoes. After sex, parasite progeny multiply to form infective spores that are injected into people by mosquito bite. Development of male and female malaria parasite gametes and their fusion to produce a diploid zygote are well understood, but the subsequent process of meiosis, development of a cyst stage and the sporogenic process .... Developmental genetics of malaria parasites. This project aims to improve our understanding of malarial genetics. The sexual cycle of malaria parasites occurs in mosquitoes. After sex, parasite progeny multiply to form infective spores that are injected into people by mosquito bite. Development of male and female malaria parasite gametes and their fusion to produce a diploid zygote are well understood, but the subsequent process of meiosis, development of a cyst stage and the sporogenic process to create haploid progeny for new infections are poorly understood in molecular genetic terms. The project aims to dissect the unique genetics of these insect stages using a rodent malaria model to generate crosses of different malaria parasite lines to determine when recombination takes effect.
    Read more Read less
    More information
    Funded Activity

    Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989920

    Funder
    Australian Research Council
    Funding Amount
    $750,000.00
    Summary
    Microbial and Cellular Imaging and Analysis Facility. The Microbial and Cellular Imaging and Analysis Facility will rapidly establish itself as one of Australia's premier science facilities. It will provide the capacity to investigate the structure and molecular dynamics of viruses and microbial, human, animal and plant cells with unprecedented high resolution in both pure and applied research settings, guided by Australia's leading experts in many research strengths. This facility addresses a c .... Microbial and Cellular Imaging and Analysis Facility. The Microbial and Cellular Imaging and Analysis Facility will rapidly establish itself as one of Australia's premier science facilities. It will provide the capacity to investigate the structure and molecular dynamics of viruses and microbial, human, animal and plant cells with unprecedented high resolution in both pure and applied research settings, guided by Australia's leading experts in many research strengths. This facility addresses a current unmet need for scientists in this country and will provide cutting-edge technologies to Australian researchers so they can better detect, understand, and treat human, animal and plant diseases and the environmental impact of climate change.
    Read more Read less
    More information

    Showing 1-7 of 7 Funded Activites

    Advanced Search

    Advanced search on the Researcher index.

    Advanced search on the Funded Activity index.

    Advanced search on the Organisation index.

    National Collaborative Research Infrastructure Strategy

    The Australian Research Data Commons is enabled by NCRIS.

    ARDC CONNECT NEWSLETTER

    Subscribe to the ARDC Connect Newsletter to keep up-to-date with the latest digital research news, events, resources, career opportunities and more.

    Subscribe

    Quick Links

    • Home
    • About Research Link Australia
    • Product Roadmap
    • Documentation
    • Disclaimer
    • Contact ARDC

    We acknowledge and celebrate the First Australians on whose traditional lands we live and work, and we pay our respects to Elders past, present and emerging.

    Copyright © ARDC. ACN 633 798 857 Terms and Conditions Privacy Policy Accessibility Statement
    Top
    Quick Feedback